Teva Pharmaceutical Industries Limited reports developments across its global pharmaceutical business, including complex generic medicines, biosimilars, pharmacy brands, and innovative medicines in neuroscience and immunology. News commonly covers financial results, investor conference presentations, R&D updates, regulatory milestones, and product or patient-support launches tied to brands and candidates such as UZEDY, PONLIMSI, and proposed biosimilars.
As an Israel-based issuer with ADSs traded under TEVA, company updates also address ADR-relevant investor communications, operating outlook materials, partnerships, and strategy around a generics platform supporting a broader biopharmaceutical portfolio.
Teva (TEVA) announced new efficacy and safety analyses of ecopipam, its investigational treatment for pediatric patients with Tourette syndrome.
A pooled post hoc analysis, conducted after the trials, found clinically meaningful tic improvement in 69.8% of 292 patients within eight weeks. An interim analysis of an ongoing open-label extension, in which treatment was known, reported a 45.6% mean reduction in tic severity scores through 18 months, with no new safety signals. That study included 118 participants with median exposure of 14.9 months. A separate post hoc analysis of 216 participants found that common co-occurring psychiatric conditions did not negatively affect efficacy or safety during the 12-week open-label period. Ecopipam's pediatric application is under FDA Priority Review.
Teva (TEVA) announced a Journal of Child Neurology review examining ecopipam’s potential to treat Tourette syndrome in pediatric patients. Ecopipam is an investigational drug that selectively blocks dopamine D1 receptors. In Phase 3, continued treatment reduced pediatric participants’ risk of tic relapse by 50% versus placebo (HR: 0.5; P=0.008). Phase 2b and 12-month open-label data showed sustained reductions in tic severity.
Common adverse events included somnolence, headache, insomnia, fatigue and anxiety. Across trials, ecopipam was not associated with clinically relevant weight gain, adverse metabolic effects or drug-induced movement disorders. The FDA granted Priority Review and Orphan Drug designation for pediatric Tourette syndrome.
Teva (TEVA) and Samsung Bioepis entered a license, development and commercialization agreement covering up to six potential biosimilar candidates. Two investigational candidates are confirmed: SB41, referencing Fasenra (benralizumab), and SB44, referencing Ilaris (canakinumab), with an option for four additional assets. Biosimilars are medicines developed to closely match existing biological medicines.
Samsung Bioepis will handle development, regulatory registration and manufacturing, while Teva will handle commercialization in the United States, Europe and Canada, with an option to expand to other territories. The companies also expanded their existing agreement to include OPUVIZ (aflibercept) in Canada.
TAPI has appointed Serge Rogasik as Chief Executive Officer to lead its global active pharmaceutical ingredients and contract development and manufacturing business.
Rogasik has more than 25 years of experience across specialty ingredients, active ingredients, specialty chemicals and life sciences. Most recently, he was President and Chief Executive Officer of Kensing, owned by One Rock Capital Partners. During his leadership, Kensing integrated four acquisitions and expanded its global footprint. He previously led growth and transformation initiatives at Vantage Specialty Chemicals and Addivant.
TAPI has more than 4,000 employees, 13 manufacturing sites and six research and development facilities. Rogasik and the TAPI team will attend CPHI Milan, October 6–8, 2026, in Hall 3, Booth A73.
Teva Pharmaceutical Industries (TEVA) received U.S. FDA approval for DEGEVMA, a denosumab biosimilar to Xgeva, across the reference product's indications. DEGEVMA is indicated to prevent skeletal-related events in patients with multiple myeloma or bone metastases from solid tumors. It is also indicated to treat certain patients with giant cell tumor of bone and hypercalcemia of malignancy that has not responded to bisphosphonates. The approval relied on evidence showing no clinically meaningful differences from Xgeva in safety, purity and potency.
DEGEVMA is Teva's second FDA-approved biosimilar in 2026, following PONLIMSI's approval in March; it is also approved in the EU. Teva anticipates launching both products in the U.S. in the coming months. DEGEVMA will be supplied as a 120mg/1.7mL injection vial. Its safety information warns of severe low blood calcium, including fatal cases, and jawbone damage.
Teva Pharmaceutical Industries (TEVA) made its Q3 2026 Aide Memoire available on its investor website on September 23, 2026.
The document compiles previously disclosed information to help investors prepare for third-quarter results, which Teva expects to release on November 3, 2026, at 7:00 a.m. ET. A conference call is scheduled for 8:00 a.m. ET that day.
Teva Pharmaceutical Industries (TEVA) will release third-quarter 2026 results on November 3, followed by an 8:00 a.m. ET conference call.
The results release is scheduled for 7:00 a.m. ET. The call will also be webcast live, with a replay available on Teva's website within 24 hours after the call ends.
Teva (TEVA) reported new study data on how healthcare providers choose VMAT2 inhibitors for treating tardive dyskinesia (TD) in patients aged ≥55 years, presented at Psych Congress 2026.
In a discrete choice experiment of 489 HCPs, somnolence (drowsiness) risk and short-term AIMS improvement were top priorities, followed by dose formulation, drug-drug interaction risk, and demonstrated long-term response. Applying these preferences to available VMAT2 inhibitors, AUSTEDO had the highest predicted choice probability across four older-patient profiles, mainly driven by lower somnolence risk, longer-term response data, and its interaction profile.
An interim analysis from the IMPACT-TD Registry showed that individuals with probable TD who remained untreated with any VMAT2 inhibitor for 24 months had persistent burden: about 89%–96% reported at least mild global impact, including 60%–74% with moderate-to-severe impact. Around 55%–69% had stable or worsening TD severity with no evidence of spontaneous resolution, while depression and anxiety scores fluctuated without sustained improvement. The company said these findings underscore the need for proactive TD management and highlight treatment attributes, such as early symptom control and tolerability, that may support long-term care.
Teva (TEVA) reported new real-world data showing that UZEDY (risperidone) extended-release injectable suspension improved treatment continuity and reduced healthcare use in adults with schizophrenia and bipolar I disorder.
In schizophrenia, a matched cohort of 1,166 patients showed once-monthly UZEDY users had fewer emergency department (ED) visits than paliperidone palmitate once-monthly (PP1m) (22.0% vs. 27.8%), a 40% lower all-cause ED visit rate, numerically fewer inpatient hospitalizations (11.1% vs. 14.8%) and lower mean monthly direct healthcare costs ($4,688.10 vs. $5,724.80), for adjusted savings of $1,036.70 per patient. Against other long-acting injectables, UZEDY patients had 3.6x higher odds of adherence, 80% lower likelihood of discontinuation and lower ED/hospitalization rates versus risperidone microspheres.
In bipolar I disorder, a retrospective chart review of 358 matched patients found lower treatment failure after switching from oral antipsychotics to UZEDY (47% vs. 63%), with longer time on treatment without mania-related hospitalizations, ED visits or discontinuation due to inadequate effectiveness.
Teva (TEVA) reported new post hoc and switching data for investigational once-monthly subcutaneous olanzapine LAI TEV-'749 from the Phase 3 SOLARIS program in adult schizophrenia.
In the long-term open-label stage, 231 of 411 participants (56%; 61%, 54% and 54% in the 318-, 425- and 531-mg groups) achieved stabilization. Among those stabilized, 10 of 231 (4%; 6%, 1% and 5%) relapsed, and 39 of 183 patients (21%; 26%, 13% and 26%) treated for at least six months met PANSS-based remission criteria. Pharmacokinetic simulations indicated that initiating TEV-'749 one day after the last oral or short-acting intramuscular olanzapine dose produced olanzapine exposure within established oral therapeutic ranges. Metabolic outcomes showed a profile consistent with daily oral olanzapine without a clear dose-dependent pattern.
TEV-'749 is not yet approved. An FDA PDUFA decision is expected in Q4 2026, and the EMA accepted the marketing application in May 2026.